MedTrace Logo

The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience

NCT03109470 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2017-04-13

No results posted yet for this study

Summary

Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients who were treated with Tocilizumab to require treatment with another biologic medication.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Janet E Pope, MD, MPH, FRCPC · Pope Research Corp.

  • John S Sampalis, BSc, BA, MSc, PHD, FACE · JSS Medical Research Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-11-30
Completion
2014-11-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03109470 on ClinicalTrials.gov